136 research outputs found
Occupation-specific social competences in vocational education and training (VET): the example of a technology-based assessment
Supersymmetric QCD corrections to and the Bernstein-Tkachov method of loop integration
The discovery of charged Higgs bosons is of particular importance, since
their existence is predicted by supersymmetry and they are absent in the
Standard Model (SM). If the charged Higgs bosons are too heavy to be produced
in pairs at future linear colliders, single production associated with a top
and a bottom quark is enhanced in parts of the parameter space. We present the
next-to-leading-order calculation in supersymmetric QCD within the minimal
supersymmetric SM (MSSM), completing a previous calculation of the SM-QCD
corrections. In addition to the usual approach to perform the loop integration
analytically, we apply a numerical approach based on the Bernstein-Tkachov
theorem. In this framework, we avoid some of the generic problems connected
with the analytical method.Comment: 14 pages, 6 figures, accepted for publication in Phys. Rev.
The effect of electric spot-welding on the mechanical properties of different orthodontic wire alloys
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Autologous haematopoietic stem cell transplantation (AHSCT) is a multistep procedure that enables destruction of the immune system and its reconstitution from haematopoietic stem cells. Originally developed for the treatment of haematological malignancies, the procedure has been adapted for the treatment of severe immune-mediated disorders. Results from ~20 years of research make a compelling case for selective use of AHSCT in patients with highly active multiple sclerosis (MS), and for controlled trials. Immunological studies support the notion that AHSCT causes qualitative immune resetting, and have provided insight into the mechanisms that might underlie the powerful treatment effects that last well beyond recovery of immune cell numbers. Indeed, studies have demonstrated that AHSCT can entirely suppress MS disease activity for 4–5 years in 70–80% of patients, a rate that is higher than those achieved with any other therapies for MS. Treatment-related mortality, which was 3.6% in studies before 2005, has decreased to 0.3% in studies since 2005. Current evidence indicates that the patients who are most likely to benefit from and tolerate AHSCT are young, ambulatory and have inflammatory MS activity. Clinical trials are required to rigorously test the efficacy, safety and cost-effectiveness of AHSCT against highly active MS drugs
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
A Clinically Successful Protocol to Suppress Autoantibody Production in SLE Patients Is Analyzed For Its Efficacy To Inhibit Natural Xenophile Antibodies (NXA)
No abstract availabl
Long-term specific suppression of antibody production by plasmapheresis and a short-term course of cyclophosphamide
No abstract availabl
- …